![Alexander Ashall-Kelly](https://profiles-cardiff.imgix.net/attachments/22?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Alexander Ashall-Kelly
Research Fellow
School of Biosciences
Publication
2025
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
2023
- Ashall-Kelly, A. 2023. Novel inhibitors of LIM kinase and GABAAR-α5 to enable therapeutics in neurological disorders. PhD Thesis, Cardiff University.
2022
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
Articles
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
Patents
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
Thesis
- Ashall-Kelly, A. 2023. Novel inhibitors of LIM kinase and GABAAR-α5 to enable therapeutics in neurological disorders. PhD Thesis, Cardiff University.